Insider Monkey
Insmed Incorporated (INSM) Price Target Raised to $211 at BofA
📈
AI Sentiment
Highly Positive
9/10
- Home
- INSM
INSM
Insmed Incorporated
as of 03-10-2026 2:56pm EST
$144.14
+$1.01
+0.71%
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 35.2B | IPO Year: | 2000 |
| Target Price: | $188.73 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.42 | EPS Growth: | -15.26 |
| 52 Week Low/High: | $60.40 - $212.75 | Next Earning Date: | 05-21-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 168.46% | Revenue Growth (next year): | 65.97% |
| P/E Ratio: | -21.82 | Index: | |
| Free Cash Flow: | -967575000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
Lewis William
Sell
Chair and CEO
INSM Mar 5, 2026
Avg Cost/Share
$145.93
Shares
10,699
Total Value
$1,562,327.58
Owned After
301,185
Smith Michael Alexander
Sell
Chief Legal Officer
INSM Feb 24, 2026
Avg Cost/Share
$155.17
Shares
24,774
Total Value
$3,859,157.05
Owned After
71,793
Lewis William
Sell
Chair and CEO
INSM Feb 19, 2026
Avg Cost/Share
$151.14
Shares
10,699
Total Value
$1,615,256.86
Owned After
301,185
Lewis William
Sell
Chair and CEO
INSM Feb 9, 2026
Avg Cost/Share
$148.01
Shares
13,396
Total Value
$1,979,763.59
Owned After
301,185
Flammer Martina M.D.
Sell
Chief Medical Officer
INSM Feb 5, 2026
Avg Cost/Share
$152.44
Shares
869
Total Value
$132,470.36
Owned After
83,243
SEC Form 4
Lewis William
Sell
Chair and CEO
INSM Feb 3, 2026
Avg Cost/Share
$156.34
Shares
3,009
Total Value
$470,427.06
Owned After
301,185
SEC Form 4
Flammer Martina M.D.
Sell
Chief Medical Officer
INSM Feb 3, 2026
Avg Cost/Share
$155.77
Shares
795
Total Value
$123,837.15
Owned After
83,243
SEC Form 4
Bonstein Sara
Sell
Chief Financial Officer
INSM Feb 3, 2026
Avg Cost/Share
$156.34
Shares
748
Total Value
$116,942.32
Owned After
79,758
SEC Form 4
Adsett Roger
Sell
Chief Operating Officer
INSM Feb 3, 2026
Avg Cost/Share
$156.17
Shares
791
Total Value
$123,530.47
Owned After
106,810
SEC Form 4
Smith Michael Alexander
Sell
Chief Legal Officer
INSM Feb 3, 2026
Avg Cost/Share
$156.27
Shares
640
Total Value
$100,012.80
Owned After
71,793
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lewis William | INSM | Chair and CEO | Mar 5, 2026 | Sell | $145.93 | 10,699 | $1,562,327.58 | 301,185 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Feb 24, 2026 | Sell | $155.17 | 24,774 | $3,859,157.05 | 71,793 | |
| Lewis William | INSM | Chair and CEO | Feb 19, 2026 | Sell | $151.14 | 10,699 | $1,615,256.86 | 301,185 | |
| Lewis William | INSM | Chair and CEO | Feb 9, 2026 | Sell | $148.01 | 13,396 | $1,979,763.59 | 301,185 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 5, 2026 | Sell | $152.44 | 869 | $132,470.36 | 83,243 | |
| Lewis William | INSM | Chair and CEO | Feb 3, 2026 | Sell | $156.34 | 3,009 | $470,427.06 | 301,185 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 3, 2026 | Sell | $155.77 | 795 | $123,837.15 | 83,243 | |
| Bonstein Sara | INSM | Chief Financial Officer | Feb 3, 2026 | Sell | $156.34 | 748 | $116,942.32 | 79,758 | |
| Adsett Roger | INSM | Chief Operating Officer | Feb 3, 2026 | Sell | $156.17 | 791 | $123,530.47 | 106,810 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Feb 3, 2026 | Sell | $156.27 | 640 | $100,012.80 | 71,793 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 19, 2026 · 99% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 19, 2026 · 99% conf.
AI Prediction BUY
1D
+2.39%
$164.84
Act: +2.43%
5D
+5.75%
$170.26
Act: -7.42%
20D
+7.09%
$172.42
Price: $161.00 Prob +5D: 99% AUC: 1.000
0001140361-26-006116
false000110450600011045062026-02-172026-02-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 17, 2026
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
Virginia
000-30739
54-1972729
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
700 US Highway 202/206
Bridgewater, New Jersey
08807
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
INSM
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02
Results of Operations and Financial Condition.
On February 19, 2026, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the three months and fiscal year ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02. The slide presentation to be used during the conference call referenced in the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information contained herein, including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 17, 2026, David W.J. McGirr notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class II director, which will occur at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”). Mr. McGirr will continue to serve as a member of the Board and chair of the Audit Committee of the Board until the Annual Meeting. Mr. McGirr’s decision to not stand for re-election to the Board was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
ITEM 9.01
Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
Description
99.1
Press release issued by Insmed Incorporated on February 19, 2026.
99.2
Insmed Incorporated February 19, 2026 Presentation.
104
Cover Page Interactive Date File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 19, 2026
INSMED INCORPORATED
By:
/s/ Michael A. Smith
Name:
Michael A. Smith
Title:
Chief Legal Officer and Corporate Secretary
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 30, 2025
0001140361-25-039789
false000110450600011045062025-10-302025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2025
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
Virginia
000-30739
54-1972729
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
700 US Highway 202/206
Bridgewater, New Jersey
08807
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.01 per share
INSM
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02 — Results of Operations and Financial Condition.
On October 30, 2025, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02 and is incorporated herein by reference. The slide presentation to be used during the conference call referenced in the press release is furnished herewith as Exhibit 99.2.
The information contained herein, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 9.01 – Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
99.1
Press release issued by Insmed Incorporated on October 30, 2025.
99.2
Insmed Incorporated October 30, 2025 Presentation.
104
Cover Page Interactive Date File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 30, 2025
INSMED INCORPORATED
By:
/s/ Michael A. Smith
Name:
Michael A. Smith
Title:
Chief Legal Officer and Corporate Secretary
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0001140361-25-029343
false000110450600011045062025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2025
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
Virginia
000-30739
54-1972729
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
700 US Highway 202/206
Bridgewater, New Jersey
08807
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
INSM
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02 — Results of Operations and Financial Condition.
On August 7, 2025, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02 and is incorporated herein by reference. The slide presentation to be used during the conference call referenced in the press release is furnished herewith as Exhibit 99.2.
The information contained herein, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 9.01 – Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
99.1
Press release issued by Insmed Incorporated on August 7, 2025.
99.2
Insmed Incorporated August 7, 2025 Presentation.
104
Cover Page Interactive Date File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 7, 2025
INSMED INCORPORATED
By:
/s/ Michael A. Smith
Name:
Michael A. Smith
Title:
Chief Legal Officer and Corporate Secretary
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
📊
AI Sentiment
Positive
6/10
Motley Fool
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Is It Time To Reassess Insmed (INSM) After A 92% One Year Surge?
📊
AI Sentiment
Positive
7/10
Compare INSM vs Leading Stocks
See how INSM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.